



Precision Medicine Approach in Prostate Cancer

Guest Editor:

Dr. Fahad Quhal

Department of Urology,
Comprehensive Cancer Center,
Medical University of Vienna,
Vienna, Austria

Deadline for manuscript
submissions:

20 October 2023


Message from the Guest Editor

Despite the recent advances in the management of prostate cancer, advanced prostate cancer remains a lethal disease—the heterogeneity of the disease results in significant variability in outcomes across patients. Substantial efforts are ongoing to identify patients who would benefit from certain treatment strategies more than others. Precision medicine allows sub-classifying patients based on biomarkers, disease features, or genomics, allowing individualized treatment approaches to achieve maximum benefit.

This Special Issue of *Journal of Personalized Medicine* aims to focus on research on the recent advances and future directions in precision medicine approaches in prostate cancer surgery. We invite researchers to address either one of the following topics or a related topic:

- Advances in the genomic classification of prostate cancer;
- Tissue- and fluid-based biomarkers in prostate cancer;
- Novel imaging modalities in evaluating and staging prostate cancer;
- Future directions of precision medicine in prostate cancer.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Senior Vice President and Director, Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Professor of Medicine Chief, Section of Hematologic Malignancies, Associate Director for Clinical Research, Division of Hematologic Malignancies and Cellular Therapy Duke Cancer Institute, Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access:— free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[@JPM_MDPI](https://twitter.com/JPM_MDPI)